PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors, tell me about this news today
05-10-2026
PMV Pharmaceuticals, Inc. announced the appointment of Matt Eckler, Ph.D., to its Board of Directors.
Key details regarding the announcement:
Role and Background: Dr. Matt Eckler joins PMV Pharma’s board bringing extensive expertise in biotechnology, corporate strategy, oncology drug development, and capital allocation. He currently serves in investment and leadership roles across the life sciences sector.
Strategic Value: The appointment comes as PMV Pharma continues to advance its precision oncology pipeline, particularly focused on discovering and developing small-molecule, tumor-agnostic therapies targeting p53 mutations (such as PC14586 / rezatapopt). Dr. Eckler’s background is expected to assist the company with strategic oversight, clinical-stage execution, and business development.
Corporate Governance: Dr. Eckler will work alongside the existing board and executive leadership team to help guide the company’s financial and pipeline priorities going forward.